The anti-MTBR-tau-targeting antibody was associated with reductions in tau uptake and spread in preclinical data. The Food and Drug Administration (FDA) has granted Fast Track designation to Bristol ...
Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease Anti-microtubule binding region-tau antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback